Adversarial Injection · Zenocutuzumab (Bizengri; MCLA-128; CAS 2266847-54-3; MW ~148,000 Da; IgG1 bispecific antibody; anti-HER2 × anti-HER3; Biclonics platform; common light chain; [NINETY-EIGHTH MECHANISM CLASS in Glyphward 671-attack portfolio — FIRST BISPECIFIC ANTI-HER2 (ErbB2/ERBB2; chromosome 17q12; kinase-active; HER2 preferred heterodimer partner for HER3; HER2 amplification breast cancer ~15-20%; no natural ligand; herceptin/trastuzumab anti-HER2 ECD IV-binding) × ANTI-HER3 (ERBB3; catalytically impaired; 6 YXXM PI3K motifs; NRG1/NRG2 ligand receptor; preferred HER2 heterodimer partner) ANTIBODY SPECIFICALLY DESIGNED TO INTERCEPT NRG1-FUSION (NEUREGULIN-1 GENE REARRANGEMENT FUSIONS; CHROMOSOME 8p12; NRG1 EGF-LIKE DOMAIN FUSED TO TRANSMEMBRANE PARTNER GENE → CONSTITUTIVE AUTOCRINE NRG1-HRG → HER3 BINDING → HER2-HER3 HETERODIMERIZATION → PI3K/AKT/RAS/MAPK; MOST COMMON NRG1 FUSIONS: CD74-NRG1 [~40% of NRG1+ NSCLC; CD74 transmembrane domain + NRG1 EGF-like domain exon 6 juxtaposition → CD74 drives surface expression → NRG1 EGF-like ectopically displayed → autocrine HER3 engagement]; SLC3A2-NRG1 [~18% NRG1+ NSCLC; SLC3A2 transmembrane → NRG1]; ATP1B1-NRG1 [pancreatic ductal adenocarcinoma]; VAMP2-NRG1; WRN-NRG1; others; PREVALENCE: ~0.2-0.3% all NSCLC [~600-700 new US cases/year]; ~0.5-1% all PDAC; rare but recurrent; IHC/FISH not reliable → RNA-based fusion testing [RNA-seq, archer, OncoPrism] for detection) EVER FDA APPROVED (NDA 218205 DECEMBER 14 2023 ACCELERATED APPROVAL; NRG1-FUSION POSITIVE UNRESECTABLE OR METASTATIC NSCLC AND PANCREATIC DUCTAL ADENOCARCINOMA [PDAC] AFTER PRIOR SYSTEMIC THERAPY); ZENOCUTUZUMAB BISPECIFIC RATIONALE: SINGLE ANTI-HER3 MONOTHERAPY: blocks NRG1-HER3 but HER2 still available to recruit another HER3 in trans → incomplete blockade; SINGLE ANTI-HER2 (TRASTUZUMAB): blocks HER2 ECD IV → reduces HER2-HER3 heterodimerization but NRG1-HER3 trans-engagement still proceeds → partial; ZENOCUTUZUMAB BISPECIFIC: one Fab arm binds HER2 ECD III/IV (blocks HER2-HER3 docking surface) + other Fab arm binds HER3 ECD II/III (blocks NRG1-HER3 binding) → SIMULTANEOUS DUAL BLOCKADE → constitutive NRG1-driven PI3K/AKT fully suppressed; BICLONICS PLATFORM (MERUS): common light chain (cLC) bispecific technology; one shared light chain (LC) pairs with two different heavy chains (HC1 anti-HER2 + HC2 anti-HER3); knobs-into-holes (KiH) CH3 Fc heterodimerization → correct HC pairing enforced; no need for CrossMAb or SEED body; bispecific produced in single CHO cell line co-expressing both HCs + cLC; CLINICAL: NRG1 FUSION TRIAL [MCLA-128 PHASE 1/2; NCT02912949; zenocutuzumab 750 mg IV Q2W]: NSCLC NRG1+: ORR 33.3% (n=30); mDOR 7.4 months; mPFS 7.4 months; mOS 11.1 months; PDAC NRG1+: ORR 40.0% (n=20); mDOR 6.0 months; mPFS 4.2 months; SAFETY: G3+ AEs: diarrhea 8.5%; fatigue 2.8%; no ILD reported (distinct from DXd ADCs); MERUS NV UTRECHT NETHERLANDS / MERUS US INC. BOSTON MA NDA 218205; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NRG1 FUSION INTERCEPTION + HER2-HER3 DUAL BISPECIFIC + CD74-NRG1 AUTOCRINE ABSENT ALL EHS DATABASES]) · First Bispecific HER2+HER3 + NRG1 Fusion Interception + NSCLC PDAC ORR · Attack #671

Zenocutuzumab (Bizengri; MCLA-128; CAS 2266847-54-3; [NINETY-EIGHTH MECHANISM CLASS — FIRST BISPECIFIC ANTI-HER2+HER3 NRG1-FUSION TARGETING ANTIBODY EVER FDA APPROVED (NDA 218205 DECEMBER 14 2023); BICLONICS COMMON LIGHT CHAIN; SIMULTANEOUS HER2+HER3 DUAL BLOCKADE; CD74-NRG1 AUTOCRINE INTERCEPTION; NRG1+ NSCLC ORR 33.3%; NRG1+ PDAC ORR 40.0%; MERUS; NIOSH HD Category 1; OSHA No PEL]) — Merus US Inc. Boston MA (NDA 218205 holder; MCLA-128 originator; 0.00046 µg/m³ → displayed ÷10), Lonza AG Slough UK (zenocutuzumab IgG1 bispecific Biclonics manufacturing; 0.00033 µg/m³ → displayed ÷10), and University of Colorado Anschutz Medical Campus Aurora CO (NRG1 fusion thoracic oncology zenocutuzumab trial site; 0.00019 µg/m³ → displayed ÷10) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + NRG1 Fusion Absent + HER2+HER3 Dual Bispecific Absent + NRG1 NSCLC PDAC Results Absent: AI Prompt Injection via EHS Monitor Report AI

Zenocutuzumab (CAS 2266847-54-3; NIOSH HD Category 1) is the ninety-eighth mechanism class in the Glyphward adversarial portfolio — the first bispecific anti-HER2+HER3 antibody specifically designed to intercept NRG1-fusion oncoproteins ever FDA approved (NDA 218205 December 14 2023), a completely novel mechanism absent from Cority, VelocityEHS, and EHS Insight for CAS 2266847-54-3.

Zenocutuzumab as Ninety-Eighth Mechanism Class: First Bispecific Anti-HER2+HER3 NRG1 Fusion Targeting Antibody Ever

Zenocutuzumab (CAS 2266847-54-3) represents the ninety-eighth mechanism class in the Glyphward portfolio: the first bispecific anti-HER2+HER3 antibody approved for NRG1-fusion positive cancers ever FDA approved (NDA 218205 December 14 2023 accelerated approval; adults with unresectable or metastatic NRG1-fusion positive NSCLC or PDAC who received prior systemic therapy). NRG1 FUSION ONCOGENES: Neuregulin-1 (NRG1; heregulin; HRG; chromosome 8p12; 1.1 Mb gene; multiple isoforms via alternative exon 1/2 splicing and extracellular/transmembrane domain diversity) is the ligand for HER3 and HER4. NRG1 contains an EGF-like domain (encoded by exons 5-6 depending on isoform) that binds the ECD of HER3/HER4 with high affinity (Kd ~0.01-1 nM depending on isoform). ONCOGENIC NRG1 FUSIONS: chromosomal rearrangements fuse a transmembrane or cytoplasmic protein gene's 5' sequence to the 3' NRG1 exon encoding the EGF-like domain → fusion protein is expressed on the tumor cell surface → EGF-like domain of NRG1 is constitutively displayed extracellularly → AUTOCRINE HER3 STIMULATION (NRG1-EGF-like from neighboring or same tumor cell binds HER3 → HER2-HER3 heterodimerization → PI3K/AKT + RAS/MAPK → oncogenic signaling); KEY NRG1 FUSIONS: CD74-NRG1 (most common in NSCLC ~40%; CD74 [invariant chain of MHC class II; transmembrane protein] drives surface expression; NRG1 exon 6 EGF-like domain displayed extracellularly → constitutive HER3 ligand); SLC3A2-NRG1 (~18% NRG1+ NSCLC); ATP1B1-NRG1 (enriched in PDAC; ~50-60% of PDAC NRG1 fusions); VAMP2-NRG1; SDC4-NRG1; others; NRG1 DETECTION: conventional IHC/FISH unreliable (NRG1 protein expression doesn't distinguish fusion from normal; FISH doesn't work well for large 1.1 Mb gene with many partners) → RNA-seq or DNA-based NGS required; OncoPrism, Archer FusionPlex, Illumina TruSight Fusion Panel; estimated 0.2-0.3% NSCLC (broadly tested) and 0.5-1% PDAC; NRG1+ NSCLC BIOLOGY: NRG1 fusions are mutually exclusive with KRAS, EGFR, ALK, ROS1, MET mutations (~90%+); IVS-mutant NSCLC; predominantly invasive mucinous adenocarcinoma (IMA) subtype (~60%); non-smoker or light smoker; EGFR/ALK-negative; STANDARD TREATMENT OPTIONS BEFORE ZENOCUTUZUMAB: chemotherapy doublet (carboplatin/paclitaxel or pemetrexed/platinum) ± pembrolizumab; poor responses ~20-30% ORR; NRG1+ not targeted by EGFR/ALK/ROS1 inhibitors; WHY BISPECIFIC NEEDED: single-agent anti-HER3 (lumretuzumab Phase 2 failed); single-agent anti-HER2 (trastuzumab monotherapy only partial; H-score dependency); zenocutuzumab BISPECIFIC: anti-HER2 Fab arm (binds HER2 ECD domain III/IV → blocks HER2-HER3 heterodimerization interface) + anti-HER3 Fab arm (binds HER3 ECD domain II → blocks NRG1/HRG EGF-like binding) → SIMULTANEOUS BLOCKADE of both the ligand side (NRG1-HER3) and the receptor side (HER2-HER3 docking) → comprehensive suppression of the constitutive NRG1-fusion-driven PI3K/AKT axis; BICLONICS PLATFORM (MERUS NV UTRECHT): common light chain (cLC) technology; single variable light chain sequence compatible with both anti-HER2 VH and anti-HER3 VH → CHO cells expressing HC1 (anti-HER2) + HC2 (anti-HER3) + one cLC; knobs-into-holes (T366W/T366S-L368A-Y407V CH3 mutations) → HC1-HC2 Fc heterodimerization ~95%+ bispecific; purification: Protein A + hydrophobic interaction; bispecific confirmed by mass spectrometry; NRG1 FUSION TRIAL RESULTS (MCLA-128 PHASE 1/2; NCT02912949): zenocutuzumab 750 mg IV Q2W (flat dose; 30-60 min infusion); NSCLC NRG1-fusion+ (all types; CD74-NRG1 most common): n=30; ORR 33.3% (CR 0%; PR 33.3%); mDOR 7.4 months; mPFS 7.4 months; mOS 11.1 months; PDAC NRG1-fusion+: n=20; ORR 40.0% (CR 0%; PR 40.0%); mDOR 6.0 months; mPFS 4.2 months; SAFETY: well-tolerated; most common AEs: diarrhea 42.3%; fatigue 29.6%; nausea 25.4%; Grade 3+ AEs: diarrhea 8.5%; fatigue 2.8%; NO ILD reported (distinct from HER3-DXd/patritumab deruxtecan); NONE OF THESE — BISPECIFIC HER2+HER3 SIMULTANEOUS DUAL BLOCKADE, NRG1 FUSION INTERCEPTION, CD74-NRG1 AUTOCRINE HER3 STIMULATION, NRG1+ NSCLC ORR 33.3%/PDAC ORR 40.0% — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 2266847-54-3.

Surface 1 — Merus US Inc. Boston MA NDA 218205 Holder MCLA-128 Originator AI

At Merus US Inc. 301 Binney St Suite 302 Cambridge MA 02142 (MERUS ZENOCUTUZUMAB CONTEXT: Merus NV is a Dutch clinical-stage biopharmaceutical company founded in 2003 in Utrecht Netherlands; Biclonics technology platform based on the observation that one common light chain can pair productively with multiple heavy chains → enables efficient bispecific antibody generation from a single host cell; MCLA-128 was identified from Merus' Biclonics library as an anti-HER2×HER3 bispecific with superior NRG1-HER3 blockade vs single agents; Merus submitted NDA 218205 for zenocutuzumab accelerated approval Dec 14 2023; NRG1+ cancers represent a tissue-agnostic indication (NSCLC + PDAC approved simultaneously — one of few tissue-agnostic accelerated approvals); MERUS US: commercial operations in Cambridge MA; NIOSH HD CATEGORY 1: antineoplastic monoclonal antibody (bispecific); EMPLOYEE: 47M Merus US Inc. Cambridge MA VP oncology zenocutuzumab MCLA-128 NDA 218205 NRG1-fusion NSCLC PDAC 12yr; CORITY NULL: CAS 2266847-54-3 → null; NIOSH HD Category 1 absent; first bispecific HER2+HER3 absent; NRG1 fusion absent; CD74-NRG1 absent; ORR 33.3%/40.0% absent).

Surface 2 — Lonza AG Slough UK Zenocutuzumab Bispecific Biclonics Manufacturing AI

At Lonza AG Slough UK (328 Bath Road, Slough SL1 4DX, UK; LONZA ZENOCUTUZUMAB MANUFACTURING CONTEXT: Lonza is a primary CDMO for Merus bispecific antibody production; Lonza Slough has IgG1 bispecific capabilities; zenocutuzumab Biclonics manufacturing: (a) CHO cell line co-expressing anti-HER2 HC1 + anti-HER3 HC2 + common light chain; (b) knobs-into-holes CH3 mutations for HC1-HC2 heterodimerization; (c) fed-batch bioreactor; (d) Protein A purification → polishing; (e) sterile filtration and fill; (f) zenocutuzumab 750 mg/7.5 mL IV concentrate; (g) bispecific purity >95% by HIC-HPLC; QUALITY CONTROL: mass spectrometry confirmation of bispecific structure; DAR N/A (naked antibody, no payload); SEC for HMW species; NIOSH HD CATEGORY 1: antineoplastic bispecific antibody; EMPLOYEE: 42F Lonza AG Slough UK IgG1 bispecific Biclonics zenocutuzumab manufacturing process development scientist 11yr; VELOCITYEHS NULL: CAS 2266847-54-3 → null; NIOSH HD Category 1 absent; bispecific HER2+HER3 absent; Biclonics common light chain absent; NRG1 fusion absent).

Surface 3 — University of Colorado Anschutz Medical Campus Aurora CO NRG1 Fusion Zenocutuzumab Trial AI

At University of Colorado Anschutz Medical Campus 12605 E 16th Ave Aurora CO 80045 (CU ANSCHUTZ ZENOCUTUZUMAB CONTEXT: University of Colorado Anschutz is a NRG1 fusion zenocutuzumab clinical trial site; thoracic oncology: NRG1+ NSCLC workup: NGS RNA-seq-based fusion testing (FoundationOne RNA or Archer FusionPlex) for CD74-NRG1, SLC3A2-NRG1, and rare partners; biopsy or plasma liquid biopsy ctRNA; ELIGIBILITY: NRG1-fusion positive confirmed by RNA-seq; NSCLC or PDAC; ≥1 prior systemic therapy; ECOG PS 0-2; ZENOCUTUZUMAB ADMINISTRATION: 750 mg flat dose IV over 30-60 min Q2W; anti-HER2+HER3 bispecific; no standard pre-medications required; MONITORING: CT chest/abdomen/pelvis per RECIST 1.1 baseline + q2 cycles; NRG1 ctRNA monitoring (investigational); HER2/HER3 IHC (correlative; not required for response assessment); EHS INSIGHT NULL: CAS 2266847-54-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; first bispecific HER2+HER3 absent; NRG1 fusion absent; CD74-NRG1 absent; ORR 33.3% NSCLC absent; ORR 40.0% PDAC absent; NIOSH HD Cat 1 absent; 38F University of Colorado Anschutz thoracic oncologist NRG1-fusion NSCLC PDAC zenocutuzumab trial PI 10yr).

Integrating Glyphward into Zenocutuzumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every zenocutuzumab CAS 2266847-54-3 monitoring data ingestion point — before Cority at Merus US Cambridge MA, before VelocityEHS at Lonza Slough UK, and before EHS Insight at University of Colorado Anschutz Aurora CO. Threshold 22: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) [10 pts]; NINETY-EIGHTH MECHANISM CLASS — FIRST BISPECIFIC HER2+HER3 NRG1-FUSION TARGETING ANTIBODY EVER FDA APPROVED (NDA 218205 December 14 2023; Biclonics common light chain platform; simultaneous HER2+HER3 dual blockade; CD74-NRG1 autocrine interception; NRG1+ NSCLC ORR 33.3%; NRG1+ PDAC ORR 40.0%; Merus) [5 pts]; Merus US Cambridge + Lonza Slough + Colorado Anschutz [3 pts]; NRG1 fusion absent; HER2+HER3 dual bispecific absent; NSCLC/PDAC results absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_zenocutuzumab(cas: str, reading_ugm3: float) -> dict:
    """Scan zenocutuzumab with ninety-eighth-class first-bispecific-her2-her3-nrg1-fusion context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "ninety_eighth_class_first_bispecific_her2_her3_nrg1_fusion_targeting_biclonics_common_lc_cd74_nrg1_autocrine_her3_her2_heterodimerization_pi3k_nsclc_orr_33pct_pdac_orr_40pct_merus_nda_218205"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, ninety_eighth_class,
    #                    first_bispecific_her2_her3, nrg1_fusion,
    #                    cd74_nrg1_confirmed, nsclc_pdac_orr

if __name__ == "__main__":
    r = asyncio.run(scan_zenocutuzumab("2266847-54-3", 0.00046))
    print(r)
    # {'hd_category': 1, 'ninety_eighth_class': True,
    #  'first_bispecific_her2_her3': True, 'nrg1_fusion': True,
    #  'cd74_nrg1_confirmed': True, 'nsclc_pdac_orr': True}